Format

Send to

Choose Destination
J Exp Med. 2019 May 6;216(5):1005-1009. doi: 10.1084/jem.20190609. Epub 2019 Apr 26.

Microbial therapeutics: New opportunities for drug delivery.

Author information

1
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
2
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA rlanger@mit.edu.
3
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.
4
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.
5
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA ctraverso@bwh.harvard.edu.
6
Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Abstract

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.

PMID:
31028093
PMCID:
PMC6504217
[Available on 2019-11-06]
DOI:
10.1084/jem.20190609

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center